Order Article Reprints

Rüsing LZ, Schweighofer J, Aschauer J, Jeryczynski G, Vospernik L, Gisslinger H, Bumberger AM, Cserna J, Riedl J, Agis H, et al. Optimizing Belantamab Mafodotin in Relapsed or Refractory Multiple Myeloma: Impact of Dose Modifications on Adverse Events and Hematologic Response in a Real-World Retrospective Study. Cancers. 2025; 17(14):2398. https://doi.org/10.3390/cancers17142398

Rüsing, Lina Zoe, Jakob Schweighofer, Julia Aschauer, Georg Jeryczynski, Lea Vospernik, Heinz Gisslinger, Armin Marcus Bumberger, Julia Cserna, Julia Riedl, Hermine Agis, and et al. 2025. "Optimizing Belantamab Mafodotin in Relapsed or Refractory Multiple Myeloma: Impact of Dose Modifications on Adverse Events and Hematologic Response in a Real-World Retrospective Study" Cancers 17, no. 14: 2398. https://doi.org/10.3390/cancers17142398

Rüsing, L. Z., Schweighofer, J., Aschauer, J., Jeryczynski, G., Vospernik, L., Gisslinger, H., Bumberger, A. M., Cserna, J., Riedl, J., Agis, H., & Krauth, M.-T. (2025). Optimizing Belantamab Mafodotin in Relapsed or Refractory Multiple Myeloma: Impact of Dose Modifications on Adverse Events and Hematologic Response in a Real-World Retrospective Study. Cancers, 17(14), 2398. https://doi.org/10.3390/cancers17142398